✦ LIBER ✦

Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial

✍ Scribed by Stephen Clement; Paresh Dandona; J.Gordon Still; Gordana Kosutic

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Glucagon-like peptide-1 receptor agonist

✍ Y. Wang; L. Li; M. Yang; H. Liu; G. Boden; G. Yang 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 692 KB

73. Preliminary results of a phase II cl

✍ Judith Peterschmitt; Elena Lukina; Nora Watman; Maryam Banikazemi; Marcelo Iastr 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Impact of interleukin-1β antibody (canak

✍ Hensen, J.; Howard, C.P.; Walter, V.; Thuren, T. 📂 Article 📅 2013 🏛 Masson Editeur 🌐 French ⚖ 582 KB

Trends in the management of arterial hyp

✍ Ralf Schiel; Ulrich A. Müller; Wadim Beltschikow; Günter Stein 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 125 KB

PDB46 COST-UTILITY OF INSULIN DETEMIR VE

✍ H Scheijbeler; M Aagren; S Nielsen; WJ Valentine; G Goodall; R Kotchie 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Clinical and immunomodulatory effects of

✍ Jorge A. Garcia; Tarek Mekhail; Paul Elson; Pierre Triozzi; Cheryl Nemec; Robert 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB